 "pharmaceutical, pharma, testing, research, doctors, health, drugs, medicine, labaratory")
US-based Gilead Sciences said that it has signed non-exclusive licensing agreements with five generic drug makers in India and Pakistan to expand the supply of antiviral drug remdesivir. The re-purposed Ebola drug is being considered as a potential therapy for coronavirus (Covid-19).
According to the agreement the companies Cipla, Hetero Labs, Jubilant Life Sciences, Mylan, and Pakistan based Ferozsons Labs, to manufacture and sell remdesivir in 127 countries. The stocks of Cipla and Jubilant were trading high on the BSE in morning trade - Jubilant was up about 5 per cent, Cipla 2.5 per cent.
Most of these 127 countries
